ABSTRACT
INTRODUCTION
Nanoparticle technology has been developed in drug delivery systems due to its ability to penetrate walls and intercellular space [1] . The nanoparticle technology used in drug delivery systems is a drug system with a carrier matrix such as a nanosphere, nanoemulsion, or nanoliposomes [2] . The definition of nanoparticles varies across several references due to their different size limits. Some papers defined the size of nanoparticles as < 1 μm [1] . The European Commission Recommendations [3] states that "a defined nanomaterial must consist of 50% or more of particles having sizes between 1-100 nm", and the other source described the size of nanoparticles as < 200 μm [4] .
Lipid nanoparticles are defined as nanoparticles with components of the lipid molecule. Lipid-based nanoparticles have some advantages such as their low toxicity for in vivo assay, their ability to improve their physical properties, drug loading efficiency, and drug release potential [5] . Lipid nanoparticle development grew rapidly in the field of nanoparticle technology due to its potential benefits in drug delivery systems, clinical treatment, and research development [6] . The complex of lipid nanoparticles using the ligand of 4-nbutylresorcinol, a derivative of resorcinol compound, can be developed as a drug in the complex form of lipid nanoparticles to improve physical instability characterized by discoloration [7] . The development of lipid nanoparticle technology aims to improve drug encapsulation and reduce leakage of active substances during the storage process [8] .
Encapsulation of drugs in complex systems of lipid nanoparticles represents the trapped amount of 4-nbutylrescinol in the lipid nanoparticle system [9] . It is important to determine the drug content in the complex system using an appropriate analytical method [10] . Chromatography, commonly used for this approach, can be used to analyze drug content in complexes or mixtures such as in multivitamins [11] , natural products [12] , and blood plasma [13] . Especially for the liposome analysis, calculation of EE% can be performed to determine free drug and is supported by High Performance Liquid Chromatography (HPLC) method [14] . An analytical method of fluorouracil (5-FU) compounds contained in nanoparticle polymers using HPLC method has been developed [15] . Other research has successfully developed HPLC methods for determining the resorcinol [16] [17] . Hence, analytical method validation of free drug in complex 4-nbutylresorcinol lipid nanoparticles in the lipid nanoparticle system should be performed since it was important to determine the efficiency of encapsulation of drug compounds in formulated lipid nanoparticles system using a validated HPLC method [10] .
In this study, a valid RP-HPLC method was developed to determine free drug content of 4-nbutylresorcinol in the liposome matrix followed by the determination of the EE%. The analytical method validation was performed for the parameter of selectivity, sensitivity, linearity, accuracy, and precision.
EXPERIMENTAL SECTION

Materials
Materials used in this study were: L-α-phosphatidylcholine from soy lecithin (pharmaceutical grade, Sigma Aldrich, USA), redistilled water, 4-nbutylresorcinol (98.1%, TCI, Japan), ethanol (analytical grade, Merck, USA), methanol (analytical grade, Merck, USA), and Phosphate Buffer Saline (PBS) (pharmaceutical grade, Biogear, China).
Instrumentation
The instruments used in this study were glassware (pyrex); hot plate, blender (Waring, America); ultraturax; bath sonicator (Elmasonic, Germany); microcentrifuge (Centurion, UK), micropipette (Socorex), analytical balance (OHAUS (min 0.01), America), analytical balance (Scaltec SBC 22 (min 0.001 g), USA), pH meter (SI Analytics), ultra-purified water (Thermo Scientific, Amerika), particle size analyzer (Horiba SZ-100, Japan); transmission electron microscopy (type JEOL JEM-1400, Japan); HPLC with UV detector (Shimadzu LC-2010C, Japan).
Procedure
Standard solution preparation
The 4-n-butylresorcinol standard stock solution was prepared as follows: 10.00 mg of 4-nbutylresorcinol were accurately weighed into a 10 mL volumetric flask, dissolved and diluted with ethanol. 
Chromatographic conditions
Calibration standard of 4-n-butylresorcinol and samples solutions were analyzed using Shimadzu LC-2010 HPLC with UV detector. The analytical column was a Phenomenex® C18 column (250 x 4.6 mm, 5 μm). Chromatography was carried out using methanol-redistilled water-glacial acetic acid 79:20:1 (v/v) as the mobile phase with pH maintained at 2.1-2.6. The flow rate of the mobile phase was maintained at 0.8 mL/min in the isocratic reverse-phase HPLC system. All the solutions were injected into HPLC system in the volume of 10 μL and detected using UV detector at 279 nm.
System suitability test
System suitability was determined from five replicate injections of the system suitability standard before sample analysis. The acceptance criteria were less than 2% relative standard deviation (%RSD) for peak area and retention time, greater than 2000 column plates number, resolution value of more than 2.0, and tailing factor of less than 2.0 [18] .
Complex lipid nanoparticle preparation
Preparation of complex lipid nanoparticle was prepared by dispersing 8.70 g phospholipid in 100 mL distilled water [19] with 0.1% (w/v) 4-n-butylresorcinol [20] . Phospholipids and water were mixed and blended for 60 sec. Further, this mixture was subjected to sonication for about 30 min at temperature 60 °C. In the early sonication process, 4-n-butylresorcinol was added as the active compound. The complex lipid nanoparticles were analyzed using particle size analyzer (PSA) to examine the particle sizes and transmission electron microscopy (TEM) to see the shape of the complex lipid nanoparticle [21] .
Analytical method validation for determining free drug content Selectivity. The selectivity test solution was obtained by transferring 300 μL of sample solutions combined with a a standard solution of 4-n-butylresorcinol at three different concentration levels (10, 15 and 20 μg/mL) into 10 mL volumetric flask for each concentration and diluted with ethanol. All the solutions were injected into HPLC system in the volume of 10 μL and detected using UV detector at 279 nm. The selectivity test was examined by peak profile identification. The resolution value greater than 2 would indicate a good separation to meet the acceptance criteria [22] . Linearity. Linearity test solutions of 4-n-butylresorcinol were prepared from the standard stock solution at eleven different concentration levels (5-55 μg/mL). The calibration curves were constructed by plotting their concentrations versus peak areas. The correlation coefficient, slope, and intercept of the calibration curve were calculated. Sensitivity. The sensitivity of the method was presented by the value of the limit of detection (LoD) and limit of quantification (LoQ). The LoD and LoQ of 4-nbutylresorcinol were determined by using the standard deviation approach as defined in Ahuja & Dong and Ermer & Miller [22] [23] . A specific calibration curve in the lowest concentration should be studied using samples containing 4-n-butylresorcinol. The LoD and LoQ values were calculated by both the residual standard deviation of a calibration curve and the y-intercepts of regression lines [24] . Accuracy and precision. The accuracy and precision of the solution were obtained by transferring 300 μL of sample solutions combined with a standard solution of 4-n-butylresorcinol at three different concentration levels (10, 15 and 20 μg/mL) into a 10 mL volumetric flask for each concentration and diluted with ethanol. All the solutions were injected into HPLC system in the volume of 10 μL and measured using UV detector at 279 nm. The accuracy and precision of the method were assessed by calculating the recovery and RSD value at three concentration levels (low, medium, high) and three replicates of each concentration.
Determination of free drug content and encapsulation efficiency (EE%)
The sample solution was obtained by transferring 500 μL of the sample solution into a micro-centrifuge tube and diluting to 1000 μL with ethanol. This solution was centrifuged for 30 min (15000 rpm). Free drug content determination of the model compound 4-nbutylresorcinol was performed using a developed HPLC method. The determined content of free 4-nbutylresorcinol presented the content of unencapsulated 4-n-butylresorcinol in the matrix of drug delivery system models within the formulation process. EE% determination was performed based on analytical data of free drug in the liposome matrix using a developed HPLC method. The calculation EE% was performed using the formula (1) as described in Chan et al. [25] .
weight of added analyte weight of unencapsulated analyte EE% x100% weight of added analyte  
RESULT AND DISCUSSION
The complex lipid nanoparticle of 4-nbutylresorcinol characteristics profile obtained from this study was presented in Table 1 . The particle size of the complex nanoparticle, described as the z-average value was measured in this study as < 200 nm and met the acceptance criteria [4] . The polydispersity index during the storage time (0-30 days) met the acceptance criteria for the polydisperse nanoparticle system of < 0.3 [26] . Complex lipid nanoparticles resulting from the heating and sonication method had a particle size similar to the previous study [20] . Morphology of complex lipid nanoparticle from TEM observation was shown in Fig. 1 .
The calculation of EE% during storage presented the stability of complex lipid nanoparticle 4-nbutylresorcinol as the drug delivery system obtained during the storage. Analytical method validation for determining free drug content in the matrix of complex lipid nanoparticle 4-n-butylresorcinol was performed in this study as follows:
System Suitability
The system suitability test for the HPLC method established was performed to assess the instrument performance parameters such as peak area %RSD, retention time %RSD, total plate number, tailing factor of 4-n-butylresorcinol peak, and resolution. The mean (n = 5) peak area %RSD was 1.37%, the mean retention time %RSD was 0.06%, the mean total plate number was 6782.8, the mean tailing factor was 1.19, and the resolution for 4-n-butylresorcinol and neighboring peak was 6.15.
Selectivity
Wavelength detection of 279 nm was determined by scanning three concentrations of standard solution (10, 20 , and 30 μg/mL) at 200-400 nm. Representative chromatogram presented in Fig. 2 showed the good separation of 4-n-butylresorcinol at the retention time of 5.494 min. Resolution of the major peak was 6.1. The chromatogram separation profile and resolution obtained in this study indicated that chromatogram separation of 4-n-butylresorcinol met the acceptance criteria since the resolution value was more than 2 [22] .
Linearity
Linearity parameter was observed in this study from the calibration curves resulting from plotting concentrations versus peak areas of 4-n-butylresorcinol in the presence of phosphatidylcholine matrix. A series of linearity standard solution (5-55 μg/mL) was injected into the HPLC system. The calibration curve equation of 4-n-butylresorcinol was obtained using equation of y = 11254x + 3994 (r = 0.999). The calibration standard curve is presented in Fig. 3 .
Sensitivity
The sensitivity of the method was presented by the value of LoD and LoQ resulting from a calculation using the standard deviation approach [22] [23] . LoD and LoQ of the method were 1.21 and 4.04 µg/mL, respectively.
Precision
The precision test was performed using the standard addition method. The three levels concentration of 4-n-butylresorcinol were added into the sample matrix and evaluated both intraday and interday as shown in Table 2 . The percentage of RSD resulting from each concentration level should not be more than 3.7% [27] . The required values of percentage RSD were accepted in the low, medium, and high concentration level of 4-n-butylresorcinol addition.
Accuracy
An accuracy test was performed using the standard addition method. The three concentration levels consisted of the low (10.30 µg/mL), medium (15.45 µg/mL), and high (20.60 µg/mL) as shown in Table 3 . The value of the recovery as the accuracy parameter at three concentration levels of 4-nbutylresorcinol were within the required range of 95-105 % [27] .
Determination of Free Drug Content and EE%
Free drug content and EE% were determined in this study. A validated HPLC method has been used to analyze free drug content of the model compound 4-nbutylresorcinol and resulted in a good separation (Fig.  2) . The EE% calculation results of 4-n-butylresorcinol in the phosphatidylcholine matrix were presented in Table  4 .
The EE% calculation was performed to observe the stability profile of complex lipid nanoparticle 4-n-butylresorcinol during the storage of day 0, 7, 14, 21, and 30. The EE% increased during storage. The aggregation formation of complex lipid nanoparticle 4-nbutylresorcinol during storage resulted in a bigger complex and enabled the drug to trap inside. The aggregation phenomenon forming the bigger complex of lipid nanoparticle 4-n-butylresorcinol might decrease the free drug in the system. However, EE% was increased during storage. The previous study [28] brought forth the insight of a new hypothesis that the decrease of EE% was correlated with the increase of the drug versus lipid ratio. The EE% was significantly affected by the alteration of the drug versus lipid ratio.
CONCLUSION
The method used in this research was validated in the parameter of selectivity (6.1), sensitivity (LoD and LoQ of the method were 1.21 and 4.04 µg/mL), linearity (0.999), accuracy (100.91-101.77), and precision (0.10-0.15). During 30 days of storage, the complex lipid nanoparticle system showed an increase in the EE% value.
